NCT02556346View on ClinicalTrials.gov

Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Chronic B-cell Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Interventions
DRUG

MT-3724

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

DRUG

MT-3724

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

DRUG

MT-3724

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

DRUG

MT-3724

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

DRUG

MT-3724

Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Sponsors
All Listed Sponsors
lead

Molecular Templates, Inc.

INDUSTRY